- Home
- IBO vs NERV Comparison
IBO vs NERV Comparison
Compare IBO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- NERV
- Stock Information
- Founded
- IBO 2018
- NERV 2007
- Country
- IBO United States
- NERV United States
- Employees
- IBO N/A
- NERV N/A
- Industry
- IBO
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- NERV Health Care
- Exchange
- IBO NYSE
- NERV Nasdaq
- Market Cap
- IBO 16.5M
- NERV 18.3M
- IPO Year
- IBO 2024
- NERV 2014
- Fundamental
- Price
- IBO $1.57
- NERV $2.19
- Analyst Decision
- IBO
- NERV Hold
- Analyst Count
- IBO 0
- NERV 1
- Target Price
- IBO N/A
- NERV $5.00
- AVG Volume (30 Days)
- IBO 32.6K
- NERV 14.3K
- Earning Date
- IBO 11-12-2024
- NERV 11-05-2024
- Dividend Yield
- IBO N/A
- NERV N/A
- EPS Growth
- IBO N/A
- NERV N/A
- EPS
- IBO 0.01
- NERV N/A
- Revenue
- IBO N/A
- NERV N/A
- Revenue This Year
- IBO N/A
- NERV N/A
- Revenue Next Year
- IBO N/A
- NERV N/A
- P/E Ratio
- IBO $187.06
- NERV N/A
- Revenue Growth
- IBO N/A
- NERV N/A
- 52 Week Low
- IBO $1.22
- NERV $2.06
- 52 Week High
- IBO $3.25
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- NERV 45.26
- Support Level
- IBO N/A
- NERV $2.08
- Resistance Level
- IBO N/A
- NERV $2.32
- Average True Range (ATR)
- IBO 0.00
- NERV 0.13
- MACD
- IBO 0.00
- NERV 0.01
- Stochastic Oscillator
- IBO 0.00
- NERV 33.33
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.